Diego Garcia-Borreguero

Summary

Publications

  1. pmc Algorithms for the diagnosis and treatment of restless legs syndrome in primary care
    Diego Garcia-Borreguero
    Sleep Research Institute, Madrid, Spain
    BMC Neurol 11:28. 2011
  2. ncbi request reprint Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute
    Diego Garcia-Borreguero
    Sleep Research Institute, Alberto Alcocer 19, 28036 Madrid, Spain
    Sleep Med 8:520-30. 2007
  3. ncbi request reprint Validation of the Augmentation Severity Rating Scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome
    Diego Garcia-Borreguero
    Fundacion Jimenez Diaz, Madrid, Spain
    Sleep Med 8:455-63. 2007
  4. doi request reprint Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks
    Diego Garcia-Borreguero
    Sleep Research Institute, Madrid, Spain
    Mov Disord 27:277-83. 2012
  5. ncbi request reprint Decreased phasic EMG activity during rapid eye movement sleep in treatment-naïve Parkinson's disease: effects of treatment with levodopa and progression of illness
    Diego Garcia-Borreguero
    Department of Neurology, Fundacion Jimenez Diaz, Madrid, Spain
    Mov Disord 17:934-41. 2002
  6. doi request reprint European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society
    Diego Garcia-Borreguero
    Sleep Research Institute, Madrid, Spain
    Eur J Neurol 19:1385-96. 2012
  7. ncbi request reprint Circadian variation in neuroendocrine response to L-dopa in patients with restless legs syndrome
    Diego Garcia-Borreguero
    Department of Neurology, Fundacion Jimenez Diaz, Madrid, Spain
    Sleep 27:669-73. 2004
  8. ncbi request reprint Parkinson's disease and sleep
    Diego Garcia-Borreguero
    Department of Neurology, Fundacion Jimenez Diaz, Madrid, Spain
    Sleep Med Rev 7:115-29. 2003
  9. ncbi request reprint Time to REST: epidemiology and burden
    Diego Garcia-Borreguero
    Sleep Research Institute, Madrid, Spain
    Eur J Neurol 13:15-20. 2006
  10. ncbi request reprint Epidemiology of restless legs syndrome: the current status
    Diego Garcia-Borreguero
    Department of Neurology, Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, Madrid, Spain
    Sleep Med Rev 10:153-67. 2006

Detail Information

Publications16

  1. pmc Algorithms for the diagnosis and treatment of restless legs syndrome in primary care
    Diego Garcia-Borreguero
    Sleep Research Institute, Madrid, Spain
    BMC Neurol 11:28. 2011
    ..Restless legs syndrome (RLS) is a neurological disorder with a lifetime prevalence of 3-10%. in European studies. However, the diagnosis of RLS in primary care remains low and mistreatment is common...
  2. ncbi request reprint Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute
    Diego Garcia-Borreguero
    Sleep Research Institute, Alberto Alcocer 19, 28036 Madrid, Spain
    Sleep Med 8:520-30. 2007
    ..The Consensus Conference sought to develop a better understanding of augmentation and generate a better operational definition for its clinical identification...
  3. ncbi request reprint Validation of the Augmentation Severity Rating Scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome
    Diego Garcia-Borreguero
    Fundacion Jimenez Diaz, Madrid, Spain
    Sleep Med 8:455-63. 2007
    ..The changes in each dimension are summed to give an ASRS total score...
  4. doi request reprint Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks
    Diego Garcia-Borreguero
    Sleep Research Institute, Madrid, Spain
    Mov Disord 27:277-83. 2012
    ..The incidence of augmentation was 3.1% higher with ropinirole than with placebo. New patients with first episodes of augmentation continued to cumulate at a stable rate over the duration of this study...
  5. ncbi request reprint Decreased phasic EMG activity during rapid eye movement sleep in treatment-naïve Parkinson's disease: effects of treatment with levodopa and progression of illness
    Diego Garcia-Borreguero
    Department of Neurology, Fundacion Jimenez Diaz, Madrid, Spain
    Mov Disord 17:934-41. 2002
    ..Potential implications for the understanding of the relationship between RBD and PD are discussed...
  6. doi request reprint European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society
    Diego Garcia-Borreguero
    Sleep Research Institute, Madrid, Spain
    Eur J Neurol 19:1385-96. 2012
    ..These guidelines were undertaken by the EFNS in collaboration with the European Neurological Society and the European Sleep Research Society...
  7. ncbi request reprint Circadian variation in neuroendocrine response to L-dopa in patients with restless legs syndrome
    Diego Garcia-Borreguero
    Department of Neurology, Fundacion Jimenez Diaz, Madrid, Spain
    Sleep 27:669-73. 2004
    ....
  8. ncbi request reprint Parkinson's disease and sleep
    Diego Garcia-Borreguero
    Department of Neurology, Fundacion Jimenez Diaz, Madrid, Spain
    Sleep Med Rev 7:115-29. 2003
    ..An adequate education of the PD patients in sleep hygiene measures and a skilled use of the medication seem necessary to prevent sleep disturbance...
  9. ncbi request reprint Time to REST: epidemiology and burden
    Diego Garcia-Borreguero
    Sleep Research Institute, Madrid, Spain
    Eur J Neurol 13:15-20. 2006
    ..Given the significant burden of morbidity associated with RLS, there is a strong case for treatment in patients with troublesome symptoms...
  10. ncbi request reprint Epidemiology of restless legs syndrome: the current status
    Diego Garcia-Borreguero
    Department of Neurology, Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, Madrid, Spain
    Sleep Med Rev 10:153-67. 2006
    ..In summary, epidemiological evidence suggests that RLS is a common neurological disorder-with high impact on many aspects of the life of those affected...
  11. doi request reprint Did Immanuel Kant have dementia with Lewy bodies and REM behavior disorder?
    Marcelo Miranda
    Department of Neurology, Clinica Las Condes, Chile
    Sleep Med 11:586-8. 2010
    ..His cognitive decline was strongly associated with a parasomnia compatible with a severe rapid eye movement (REM) behavior disorder (RBD) and dementia with Lewy bodies...
  12. doi request reprint The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group
    Diego Garcia-Borreguero
    Sleep Research Institute, Madrid, Spain
    Sleep Med 14:675-84. 2013
    ....
  13. doi request reprint Dopaminergic augmentation of restless legs syndrome
    Diego Garcia-Borreguero
    Sleep Research Institute, Alberto Alcocer 19, Madrid, Spain
    Sleep Med Rev 14:339-46. 2010
    ..RLS is treated by maintaining low doses of dopaminergic agents and ensuring iron sufficiency. Non-dopaminergics and opiates can be used when patients experience augmentation with more than one dopaminergic agent...
  14. ncbi request reprint Augmentation as a treatment complication of restless legs syndrome: concept and management
    Diego Garcia-Borreguero
    Sleep Research Institute, Alberto Alcocer 19, 28036 Madrid, Spain
    Mov Disord 22:S476-84. 2007
    ..The present article reviews our current knowledge on clinical diagnosis, evaluation, pathophysiology, and treatment recommendations for this condition...
  15. ncbi request reprint Efficacy and tolerability of sumanirole in restless legs syndrome: a phase II, randomized, double-blind, placebo-controlled, dose-response study
    Diego Garcia-Borreguero
    Department of Neurology, Fundacion Jimenez Diaz, Sleep Disorders Unit, Universidad Autonoma de Madrid, Madrid, Spain
    Sleep Med 8:119-27. 2007
    ..To compare the efficacy, safety and tolerability of sumanirole with placebo in patients with idiopathic restless legs syndrome (RLS)...
  16. ncbi request reprint A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome
    Diego Garcia-Borreguero
    Sleep Research Institute, Alberto Alcocer 19, 28036 Madrid, Spain
    Sleep Med 8:742-52. 2007
    ..To assess the long-term safety and efficacy of ropinirole in the treatment of patients with restless legs syndrome (RLS) over 52 weeks...